<DOC>
	<DOC>NCT02592408</DOC>
	<brief_summary>This is a randomized controlled trial to assess the efficacy and safety of the national malaria treatment guidelines, asses the efficacy and safety of artesunate and sulphadoxine - pyrimethamine (AS+SP) for treatment in uncomplicated P. falciparum and P. vivax malaria and the hematologic effect of 14 days routine primaquine based radical cure in patients suffering from a P. vivax or mixed infection.</brief_summary>
	<brief_title>A Study to Assess Current Standard Malaria Treatment Guidelines in the Republic of the Sudan</brief_title>
	<detailed_description />
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Artesunate</mesh_term>
	<mesh_term>Sulfadoxine</mesh_term>
	<mesh_term>Primaquine</mesh_term>
	<mesh_term>Pyrimethamine</mesh_term>
	<criteria>Age ≥ 12 months P. vivax or P. falciparum monoinfection or P. vivax / P. falciparum mixed infection Presence of axillary temperature ≥ 37.5°C or history of fever during the past 24 hrs Able to tolerate oral medication Able and willing to comply with the study protocol for the duration of the study Informed consent from the patient or from a parent or guardian in the case of children Bodyweight ≤5kg Presence of general danger signs in children aged under 5 years or signs of severe malaria in any patient according to the definitions of WHO Presence of severe malnutrition Acute anaemia &lt;8g/dL Regular medication, which may interfere with antimalarial pharmacokinetics History of hypersensitivity reactions or contraindications to any of the drug(s) tested or used as alternative treatment(s) A positive pregnancy test or lactating.</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>